在胰腺癌中,BAP1调节HSF1活动和癌症免疫力
Weiwei Yuan1,2, Qiyue Zhang2,3, Yuhan Zhao2,3
1Department of General Surgery, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, 450008, China.
Journal of experimental & clinical cancer research : CR
|October 1, 2024
概括
在胰腺管腺癌 (PDAC) 中的BAP1缺失会通过抑制HSF1.1引起免疫治疗耐药性. 抑制SIRT1可以逆转这种抗性,为PDAC患者提供新的治疗策略.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 分子生物学分子生物学
背景情况:
- 胰腺管道腺癌 (PDAC) 在很大程度上对单剂免疫疗法不敏感.
- 在约27%的PDAC病例中发现的BAP1删除与预后不佳相关,但其在免疫抵抗中的作用尚不清楚.
研究的目的:
- 研究BAP1删除如何影响PDAC中的免疫治疗反应的机制.
- 确定潜在的治疗点,以克服BAP1缺乏的PDAC中的免疫抵抗.
主要方法:
- 使用Bap1淘汰和控制KPC小鼠模型和同基因异种移植.
- 采用免疫沉,RT-qPCR,光酶和转录组分析.
- 评估SIRT1抑制效果和与使用流细胞计的抗PD-1治疗的协同作用.
主要成果:
- 删除BAP1通过抑制HSF1转录活性来促进PDAC免疫抵抗.
- BAP1与SIRT1在结合乙化HSF1方面竞争,保持HSF1-HSP70相互作用和染色质脱离.
- 在BAP1缺乏的PDAC模型中,SIRT1抑制逆转了免疫疗法不敏感性.
结论:
- 阐明了BAP1通过HSF1.1调节PDAC免疫反应的新机制.
- 确定SIRT1抑制作为一种有前途的策略,以提高BAP1缺乏PDAC的免疫疗法的疗效.
相关概念视频
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
The Intrinsic Apoptotic Pathway
6.4K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
6.4K
Abnormal Proliferation
4.5K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
Regulation of Hematopoietic Stem Cells
3.2K
All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
3.2K
PI3K/mTOR/AKT Signaling Pathway
3.4K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.4K
Regulation of Angiogenesis and Blood Supply
2.5K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.5K


